Australian Biotechnology News journalist Ruth Beran asked Axon Instruments founder Alan Finkel if he had any advice for Australian companies with an eye on the world stage. Here is his reply.

With Biotechnology Innovation Fund and R&D Start grants rolled into the new Commercial Ready, the Australian biotech sector may face a post-BIF bust, writes Michael Vitale.

The Q2 venture financing statistics have been compiled, and the news is not all that bad. The modest recovery in the general US economic environment seems to be extending to the bio-IT sector. Both the number of companies being funded and the amount of capital raised are improving, although the figures may still mask some concerns.